Table 2.
Acquisition rates of CRPA, CRAB, and CRE in clinical specimens between the intervention and control periods
| Intervention period, per 1000 person-days (95% CI) |
Control period, per 1000 person-days (95% CI) |
Incidence rate ratio (95% CI) | P value | |
|---|---|---|---|---|
| Modified intention-to-treat analysisa | ||||
| Total | 1.75 (0.87–3.13) | 3.33 (2.16–4.92) | 0.53 (0.23–1.11) | 0.07 |
| CRPA | 0.32 (0.04–1.15) | 1.07 (0.46–2.10) | 0.30 (0.03–1.50) | 0.10 |
| CRAB | 0.80 (0.26–1.86) | 1.73 (0.92–2.96) | 0.46 (0.13–1.37) | 0.13 |
| CRE | 0.80 (0.26–1.86) | 0.93 (0.38–1.92) | 0.85 (0.21–3.12) | 0.79 |
CRPA carbapenem-resistant P. aeruginosa; CRAB carbapenem-resistant A. baumannii; CRE carbapenem-resistant Enterobacterales; CI confidence interval
aExcluding SICU2 in both periods 1 and 2